Авторы

  • Najmutdinova D.K., Mahmadullayeva Sh.S.

Ключевые слова:

tuxumdonlar polikistoz sindromi (TPS), insulinrezistentlik, HOMA-IR, glikirlangan gemoglobin, glyukoza, metabolik buzilishlar.

Библиографические ссылки

1. Teede H.J., Tay C.T., Laven J.J.E., Dokras A., Moran L.J., Piltonen T.T., et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 108(10):2447–2469. doi:10.1210/clinem/dgad463.

2. Stener-Victorin E., Teede H., Norman R.J., Legro R., Goodarzi M.O., Dokras A., Laven J., et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024;10(1):27. doi:10.1038/s41572-024-00511-3.

3. Zhao H., Zhang J., Cheng X., Nie X., He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023;16:9. doi:10.1186/s13048-022-01091-0.

4. Amisi C.A. Markers of insulin resistance in polycystic ovary syndrome women: an update. World J Diabetes. 2022;13(3):129–149. doi:10.4239 /wjd. v13.i3.129.

5. Mansour A., Mirahmad M., Aghajanova L., et al. Risk factors for insulin resistance related to polycystic ovarian syndrome in Iranian population. Sci Rep. 2023; 13:9446. doi:10.1038/s41598-023-375 13-2.

6. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7): 412–419. doi:10.1007/BF00280883.

7. Tosi F., Bonora E., Moghetti P. Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod. 2017;32(12):2515–2521. doi: 10.1093/humrep/dex308.

8. Szkodziak P., Szkodziak F., Trzeciak K., Woźniak S., Mlynarczyk M., Paszkowski T. Insulin resistance in polycystic ovary syndrome phenotypes and the vicious cycle model in its etiology. Sci Rep. 2025. doi:10.1038/s41598-025-26718-2.

9. Lerchbaum E., Schwetz V., Giuliani A., Obermayer-Pietsch B. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Hum Reprod. 2013;28 (9):2537–2544. doi:10.1093/humrep/det255.

10. Goldberg A., Fruhbeck G., Teede H.J., et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25(4):e13653.

11. Belsti Y., Enticott J., Azumah R., Tay C.T., Moran L.J., Ma R.C.W., et al. Diagnostic accuracy of oral glucose tolerance tests, fasting plasma glucose and haemoglobin A1c for type 2 diabetes in women with polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Metab Syndr. 2024;18 (1):102970. doi:10.1016/j.dsx.2024.102970.

12. Parker J., Briden L., Gersh F.L. Recognizing the Role of Insulin Resistance in Polycystic Ovary Syndrome: A Paradigm Shift from a Glucose-Centric Approach to an Insulin-Centric Model. J Clin Med. 2025;14(12):4021. doi:10.3390/jcm14124021.

13. Biernacka-Bartnik A., Kocełak P., Owczarek A.J., Chudek J., Olszanecka-Glinianowicz M. The cut-off value for HOMA-IR discriminating insulin resistance based on the SHBG level in women with polycystic ovary syndrome. Front Med. 2023; 10:11 00547. doi:10.3389/fmed.2023.1100547.

14. Lewandowski K.C., Płusajska J., Horzelski W., Bieniek E., Lewiński A. How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance index. Arch Med Sci. 2019;15(3):613–618.

15. Prosperi S., Chiarelli F. Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum. Front Endocrinol. 2025; 16:16 69716. doi:10.3389/fendo.2025.1669716.

16. Glintborg D., Kolster N.D., Ravn P., Andersen M.S. Prospective Risk of Type 2 Diabetes in Normal Weight Women with Polycystic Ovary Syndrome. Biomedicines. 2022;10(6):1455. doi:10.33 90/biomedicines10061455.

17. Tay C.T., Mousa A., Teede H.J., et al. 2023 International evidence-based PCOS guideline update: insights from a systematic review and meta-analysis on elevated clinical cardiovascular disease in polycystic ovary syndrome. J Am Heart Assoc. 2024;13:e033572. doi:10.1161/JAHA.123.033572.

18. Pililis S., Lampsas S., Kountouri A., Pliouta L., Korakas E., Livadas S., et al. The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment. Medicina. 2024;60(10):1656. doi:10.33 90/medicina60101656.